



New Drug Update

SERIES 31

FEB 2022

Contents:

FDA APPROVED DRUGS

1. COVID-19 VACCINE, mRNA
2. FARICIMAB – SVOA
3. TEBENTAFUSP- TEBN
4. ABROCITINIB
5. MOMETASONE FUROATE & OLOPATADINE HYDROCHLORIDE
6. DARIDOREXANT

CDSO APPROVED DRUG:

1. TRIAMCINOLONE HEXACETONIDE



1.COVID-19 VACCINE, mRNA (SPIKEVAX)

DATE OF APPROVAL: Jan 31, 2022

MECHANISM OF ACTION:

An mRNA vaccine that works by using snippets of a virus’s genetic material (rather than an inactivated or weakened form of the virus itself) to build the proteins that trigger the body’s protective immune response

INDICATION:

Active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

DOSAGE FORM:

Intramuscularly as a series of two doses (0.5 mL each) one month apart

2. FARICIMAB - SVOA

DATE OF APPROVAL: Jan 28, 2022

MECHANISM OF ACTION:

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor

INDICATION:

Neovascular (Wet) Age-Related Macular Degeneration, Diabetic Macular Edema

DOSAGE FORM:

Intravitreal injection

CONTACT US:

Department of Pharmacology,
KMCHHSR

Email: hodpharmacology@
kmchihsr.edu.in

3. TEBENTAFUSP- TEBN

DATE OF APPROVAL: Jan 25, 2022

MECHANISM OF ACTION:

A bispecific gp100 peptide-HLA-directed CD3 T cell engager

INDICATION:

HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma

DOSAGE FORM:

Intravenous injection

4. ABROCITINIB

DATE OF APPROVAL: Jan 14, 2022

MECHANISM OF ACTION:

Janus Kinase inhibitor that modulates multiple cytokines involved in the pathophysiology of Atopic dermatitis including interleukin IL-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin

INDICATION:

Refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable

DOSAGE FORM:

Tablets for oral use

5. MOMETASONE FUROATE & OLOPATADINE HYDROCHLORIDE

DATE OF APPROVAL: Jan 13, 2022

MECHANISM OF ACTION:

Olopatadine, a histamine-1 (H1)-receptor inhibitor, and mometasone furoate, a corticosteroid

INDICATION:

Symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older

DOSAGE FORM:

Nasal spray

REFERENCES:

1. US Food and Drug Administration. Novel drug approvals; USA [Internet] 2022 [cited 2022 Feb 05]. Available from: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2022>
2. Drugs.com. New drug approvals; New zealand [Internet] 2022 [cited 2022 Feb 05]. Available from: <https://www.drugs.com/newdrugs.html>
3. Central Drugs Standard Control Organization. List of approved new drugs; New Delhi [Internet] 2022 [cited 2022 Feb 05]. Available from: https://cdsco.gov.in/openncms/openncms/en/Approval_new/Approved-New-Drugs/

6. DARIDOREXANT

DATE OF APPROVAL: Jan 7, 2022

MECHANISM OF ACTION:

Orexin receptor antagonist

INDICATION:

Adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance

DOSAGE FORM:

Tablets

CDSCO APPROVED DRUG

1. TRIAMCINOLONE HEXACETONIDE

DATE OF APPROVAL: Jan 20, 2022

CLASS OF DRUG: Corticosteroid

INDICATION: For intraarticular, intra-synovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases including rheumatoid arthritis and Juvenile Idiopathic Arthritis, Osteoarthritis and post-traumatic arthritis, Synovitis, tendinitis, bursitis, and epicondylitis

DOSAGE FORM:

Injectable suspension 20mg/ml

